Quantcast
Viewing all articles
Browse latest Browse all 3193

Alnylam eyes bigger diseases in more tissue types at ‘inflection point’ for siRNA

Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top scientists believe they are just starting to scratch the full potential of its gene-silencing siRNA ...

Viewing all articles
Browse latest Browse all 3193

Trending Articles